SRNT 2017

      Date
      Mar 8, 2017 - Mar 11, 2017
      Location
      Florence, Italy

       This year there are presentations on a number of pivotal clinical trials, plus hot topics in the field of tobacco use epidemiology, genomics, biomarkers, cue reactivity, e-cigarettes, cigar use, waterpipes, smokeless tobacco, secondhand exposure, and tobacco product regulation. This year, there is a strong focus on concurrent use of tobacco with other psychoactive substances and drugs. Findings from basic science, pre-clinical and clinical studies are discussed to understand complex interactions between nicotine and other substances. At this event, PMI scientists present 6 research papers including one on the analysis of biomarkers of exposure reductions in carbon heated tobacco products. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.